America's Blood Centers®
It's About Life.

ABC NEWSLETTER

CURRENT EVENTS AND TRENDS IN BLOOD SERVICES

Visit ABC's Web site at: www.americasblood.org

2025 #20 **June 23, 2025**

INSIDE:

Secondary Analysis of MINT Randomized Trial Published in *JAMA* 2
REGULATORY NEWS....3
WORD IN WASHINGTON 3
Register for the June ADRP Webinar: "From Partnership to Purpose:4
Strengthening Hospital Relationships".....4
SAVE THE DATE: ABC WELC *Rise & Lead Workshop* November 13th-14th 4
May *Blood Bulletin* Published.....4
RECENT REVIEWS.....5
MEMBER NEWS.....5
GLOBAL NEWS 6
COMPANY NEWS 7
CALENDAR.....8
POSITIONS.....9

Congressional Champions Honored by ABC

America's Blood Centers (ABC) recently recognized the first-ever winners of its Congressional Champions Awards. As a part of Blood Advocacy Week 2025 festivities, Senator Patty Murray (D-Wash.) and Congresswoman Mariannette Miller-Meeks, M.D. (R-Iowa) were honored for demonstrating exceptional commitment to supporting the U.S. blood supply and advocating for community blood centers and blood donation.

ABC Chief Executive Officer Kate Fry, MBA, CAE stated in the news release, "ABC is proud to recognize Senator Murray and Congresswoman Miller-Meeks as our inaugural Congressional Champions. Their unwavering support for America's community blood centers and their dedication to ensuring a safe and strong blood supply exemplifies extraordinary leadership, We look forward to continuing our work with these members of Congress and building more champions to help address the challenges facing our blood supply and promote the importance of blood donation across the country."

ABC member blood center Bloodworks Northwest nominated Senator Murray for this award the news release explained, "in recognition of her exceptional contributions to public health and unwavering advocacy for blood donation. Throughout her career, Senator Murray has consistently championed the critical role of blood donation in saving lives. During the COVID-19 pandemic, as Chair of the Senate HELP Committee, she worked tirelessly to support America's community blood centers and ensure a stable blood supply. Senator Murray's efforts demonstrate her commitment to supporting others and empowering individuals to contribute, aligning with the principles of blood donation and the mission of blood centers nationwide."

Congresswoman Miller-Meeks, nominated by ABC member ImpactLife, "has been a vocal and dedicated advocate for blood donation. Her efforts include touring blood centers to gain firsthand knowledge of the logistical challenges involved in collecting, processing, and distributing blood products; addressing hurdles in donor eligibility guidelines, and participating in public service announcements, both individually and with fellow members of the GOP Doctors Caucus. In these messages, Congresswoman Miller-Meeks has encouraged Americans to donate blood and raised awareness about the critical need for a strong blood supply."

(Source: ABC News Release, 6/12/25)

Secondary Analysis of MINT Randomized Trial Published in *JAMA*

Authors of a paper published in *JAMA Internal Medicine* performed a secondary analysis of the Myocardial Ischemia and Transfusion (MINT) randomized trial. They sought to, "determine if a liberal transfusion strategy compared with a restrictive transfusion strategy affected 30-day post-randomization quality of life (QOL)." Prior results from the MINT trial published in 2023 found that, "in patients with acute myocardial infarction and anemia, a liberal blood transfusion strategy did not significantly reduce the risk of recurrent myocardial infarction or death at 30 days. Trial end points suggest[ed] some benefit of a liberal blood transfusion strategy over a restrictive blood transfusion strategy, but additional studies would be needed to confirm that conclusion."

The investigators of the secondary analysis have reported that, "[o]ur primary analysis did not demonstrate any significant difference in health-related QOL 30 days after randomization by keeping Hb levels above 10 g/dL in the liberal transfusion strategy group compared with lower Hb levels in the restrictive transfusion strategy group. This suggests that higher Hb levels maintained with red blood cell (RBC) transfusion may not offer significant benefits to QOL in patients with myocardial ischemia (MI) and anemia. [Additionally,] confidence in the finding from the primary analysis that transfusion does not affect overall QOL in the population at 30 days should be high. The results also have significant practice implications and suggest that the transfusion strategy during hospitalization for patients with acute MI and anemia does not influence post-discharge QOL as an important clinical outcome."

The authors of the secondary analysis wrote in the paper that limitations included, "the present analyses may be underpowered and vulnerable to biases, and the results may not be generalizable to the entire MINT trial cohort. In addition, QOL was not assessed at baseline, and so we are unable to determine whether it changed with or without transfusion. Multiple subgroups were analyzed in this study, which increases the chance that some of the positive findings could be false positives (type 1 error)…[W]e only measured QOL once 30 days post-randomization, and we may have missed either earlier or more nuanced intermittent changes in QOL that can occur over time."

Citation: Prochaska, M., Portela, G., Brooks, M., *et al*. "Transfusion Strategy Effect on Quality of Life in Patients With Myocardial Infarction and Anemia: A Secondary Analysis of the MINT Randomized Clinical Trial." *JAMA Internal Medicine*. 2025.

The *ABC Newsletter* (ISSN #1092-0412) is published by America's Blood Centers® and distributed by e-mail. Contents and views expressed are not official statements of ABC or its Board of Directors.

ABC advocates for and advances policies that promote the role of independent blood centers in providing life-saving blood products and recognizes the continuous need for a safe and robust blood supply. ABC exists to advocate for laws and regulations recognizing the essential role that independent blood centers play in the health care system; promote partnerships, policies, and programs that increase awareness about the need for blood donation; and serve as a thought leader in the advancement of evidence-based medical and scientific solutions related to health and safety.

America's Blood Centers
Chief Executive Officer: Kate Fry
Chief Medical Officer: Jed Gorlin
Editor: Mack Benton
Subscriptions Manager: Leslie Maundy
Annual Subscription Rate: $420

Send subscription queries to
memberservices@americasblood.org
America's Blood Centers
1717 K St. NW, Suite 900, Washington, DC 20006
Phone: (202) 393-5725
Send news tips to newsletter@americasblood.org.

REGULATORY NEWS

The U.S. Food and Drug Administration (FDA) has published a notice in the *Federal Register* titled "Request for Nominations for Individuals and Consumer Organizations for Advisory Committees." Included in the request is the Blood Products Advisory Committee (BPAC). According to the agency, the committee is responsible for, "review[ing] and evaluat[ing] available data concerning the safety, effectiveness, and appropriate use of blood products derived from blood and serum or biotechnology which are intended for use in the diagnosis, prevention, or treatment of human diseases as well as the safety, effectiveness, and labeling of the products, on clinical and laboratory studies involving such products, on the affirmation or revocation of biological product licenses, and on the quality and relevance of FDA's research program which provides the scientific support for regulating these products." One voting member position is being sought from individuals who are, "[k]nowledgeable in the fields of clinical and administrative medicine, hematology, immunology, blood banking, surgery, internal medicine, biochemistry, engineering, biological and physical sciences, biotechnology, computer technology, statistics, epidemiology, sociology/ethics, and other related professions."

(Source: *Federal Register* Notice, 6/13/25)

WORD IN WASHINGTON

***STAT News* reported on June 18th that Nicole Verdun, MD, director of the Office of Therapeutic Products (OTP), and deputy director of OTP Rachael Anatol, PhD at the U.S. Food and Drug Administration's Center for Biologics Evaluation and Research (CBER) have been placed on administrative leave.** Dr. Verdun assumed the role of director in July 2023 and previously served as the director of the Office of Blood Research and Review (OBRR) from 2018-2023.

(Source: *STAT News*, "Top gene therapy regulator forced out at FDA," 6/18/25)

CBER Director Vinay Prasad, MD, MPH has also been named chief medical and science officer at FDA. *STAT News* reported that FDA Commissioner Martin Makary, MD, MPH wrote in an announcement to agency staff that, "in this capacity, [Dr. Prasad] will serve as a trusted advisor to the FDA Commissioner and other senior officials on cross-cutting and emerging medical and scientific issues impacting regulatory science and public health."

(Source: *STAT News*, "Vinay Prasad named chief medical and science officer at FDA," 6/18/25)

The U.S. Food and Drug Administration (FDA) has announced the Commissioner's National Priority Voucher (CNPV) program. The program established that a, "new voucher may be redeemed by drug developers to participate in a novel priority program by the FDA that shortens its review time from approximately 10-12 months to 1-2 months following a sponsor's final drug application submission. The new CNPV process convenes experts from FDA offices for a team-based review rather than using the standard review system of a drug application being sent to numerous FDA offices. Clinical information will be reviewed by a multidisciplinary team of physicians and scientists who will pre-review the submitted information and convene for a one-day 'tumor board style' meeting." According to the news release, the health priorities that should be addressed by companies applying for the vouchers are:

- "a health crisis in the U.S.;
- [d]elivering more innovative cures for the American people;
- [a]ddressing unmet public health needs; [and]
- [i]ncreasing domestic drug manufacturing as a national security issue."

(Source: FDA News Release, 6/17/25)

America's Blood Centers®
It's About *Life.*

INSIDE ABC

The programs and services described in the Inside ABC section are available to ABC member blood centers and their staffs only, unless otherwise specified.

Register for the June ADRP Webinar: "From Partnership to Purpose: Strengthening Hospital Relationships"

Registration is open for the Wednesday, June 25th ADRP Webinar: "From Partnership to Purpose: Strengthening Hospital Relationships." This event aims to, "help blood centers deepen their hospital partnerships and elevate the donor-to-patient journey." Hear speakers share programs and strategies to deliver value-added services that keep hospital clients engaged and loyal, while gaining practical ideas for successfully onboarding new hospital partners and ensuring long-term collaboration using ADRP's newest Hospital Partnership Idea Book. Whether you're strengthening existing connections or forging new ones, this session is packed with actionable takeaways to help.

SAVE THE DATE: ABC WELC *Rise & Lead Workshop* November 13th-14th

Rise & Lead
A WOMEN'S LEADERSHIP WORKSHOP

ABC is excited to announce that the 2025 ABC Women's Executive Leadership Community (WELC) *Rise & Lead Workshop* will take place November 13th-14th in San Antonio, Texas at the Westin Riverwalk. Book now to secure the discounted rate. Registration will open in August. This workshop is designed for women in leadership positions, emerging leaders, and professionals seeking personal and professional growth. It also welcomes individuals who want to cultivate diverse perspectives. Attendees will engage in an intimate, engaging, and interactive environment focused on networking, mentorship, and meaningful discussions on leadership and growth. Please contact us with questions.

May *Blood Bulletin* Published

ABC has published the May 2025 edition of the *Blood Bulletin* titled "Neonatal Transfusion Support — Modifications and Preparations of Red Cell Transfusions — A Case Study." The issue was written by Daniela Hermelin, MD, Chief Medical Officer at ImpactLife; Theresa Nester, MD, Co-Chief Medical Officer at Bloodworks Northwest; Ruchika Goel, MD, Senior Medical Director, Corporate Medical Affairs at Vitalant National Office; Kip Kuttner, DO, Vice President and Medical Director at Miller-Keystone Blood Center; Nanci Fredrich, RN, BSN, MM, Transfusion Safety Officer at Versiti Blood Center of Wisconsin; Courtney Hopkins, DO, Vice President, Corporate Medical Director at Vitalant; Louis Katz, MD, Chief Medical Officer Emeritus at ImpactLife; Debra Smith, MD, PhD, MBA, Chief of Transfusion Medicine Services at Banner University Medical Center; Kirsten Alcorn, MD, Co-Chief Medical Officer at Bloodworks Northwest; Richard Gammon, MD, Medical Director, Blood Bank & Transfusion Services at Moffitt Cancer Center; and Jed Gorlin, MD, MBA, Chief Medical Officer at ABC. Contributors for this *Blood Bulletin* included: Amit M. Mathur MBBS, MD, MRCP (UK), Director, Division of Neonatal Perinatal Medicine, Department of Pediatrics, Saint Louis University School of Medicine and SLUCare Group at SSM Health; Edward F. Bell, MD, Professor of Pediatrics and Neonatologist, University of Iowa; and Nabiha Huq Saifee MD, PhD, Medical Director of Transfusion Service, Seattle Children's. *Blood Bulletin* is a quarterly publication reviewed and edited by ABC's Scientific, Medical, and Technical (SMT) Publications Committee.

RECENT REVIEWS

Platelet Safety in the Current Era. A review published in *Vox Sanguinis* summarizes presentations made "at the International Society of Blood Transfusion (ISBT) Congress [in] June 2024, [by the] Transfusion-Transmitted Infectious Diseases Working Party's Bacterial Subgroup members, along with invited speakers [who] presented their approaches to enhance platelet components (PC) safety and prevent septic transfusion reactions (STRs)." Of note, the American Red Cross (ARC) reported seven STRs between 2018 and 2021 due to contaminated PC units predominantly involving *Acinetobacter calcoaceticus-baumannii complex*, either alone or in combination with *Staphylococcus saprophyticus* and/or *Leclercia adecarboxylata*." The review further explained that, "[t]hree of the seven STRs had fatal [outcomes.] The STRs occurred despite screening with culture or rapid methods, or treatment with pathogen reduction technologies (PRT)." The Australian Red Cross Lifeblood has adopted, "a large volume delayed sampling (LVDS) testing algorithm in 2021." They reported that, "[t]here were two STR cases involving a double apheresis PC" in 2024 with *Bacillus thuringiensis* and *Bacillus cereus*. The authors also noted that, "Canadian Blood Services has adopted a proactive strategy and beg[a]n phase-in implementation of PRT in January 2022. [Data so far indicate] promising results, with no STRs observed at the time [of the paper being submitted for publication.]" The Établissement Français du Sang, the French national transfusion service began, "the use of PRT in 2006 with full implementation in November 2017." The paper explained that, "[t]wo STRs were reported between 2018 and 2023: one with *B. cereus* and the other with *B. mobilis*…In 2023, a STR case involving a three-day old PC contaminated with *B. mobilis* was reported in a patient who received a PC pool." NHS Blood and Transplant (NHSBT), the national blood provider for England and transplant services for the United Kingdom (UK) reported that the, predominant PC contaminants were gram positive skin flora with *Cutibacterium acnes*…The most frequently detected organisms included *Streptococcus dysgalactiae* at 29.1 percent, *S. aureus* at 17.7 percent and *Streptococcus pneumoniae* at 11.4 percent." The authors of the paper concluded that, "advancement in technologies in the last decades have resulted in a decrease in the incidence of STRs. [A residual] safety risk remains, stressing the importance of PC visual inspection before transfusion, along with strong hemovigilance systems. Notably, *Bacillus spp*. were identified as a remaining cause of STRs."

Citation: García-Otálora, M.-A., McDonald, C., Bearne, J., *et al*. "Platelet component safety in the era of new advancements in bacterial screening and pathogen reduction: A congress report of the 2024 ISBT Transfusion-Transmitted Infectious Diseases Working Party, Bacteria Subgroup." *Vox Sanguinis*. 2025.

Contributed by Richard Gammon, MD

MEMBER NEWS

Kentucky Blood Center (KBC) has upgraded its Corbin location, according to June 4th announcement. "The new space [has] considerably more square footage to enhance operations [as the move increased] square footage from 1,900 to 3,100. Operationally, that has allowed KBC to add two phlebotomy beds, a Trima machine for more available platelet appointments, and more storage and a bigger nurse's station to better serve donors." KBC Chief Executive Officer (CEO) Bill Reed added in the announcement, "Tri-County donors have shown a great dedication to saving local lives. Outgrowing a space in just three years is a testament to the commitment donors in Southern Kentucky have made to providing local hospitals with a healthy blood supply. We are grateful to be a part of the community and look forward to many more years in our new space." The Tri-County Donor Center has, "registered more than 7,500 donors, collected more than 6,600 products and brought in nearly 800 first-time donors," since it opened in 2022.

(Source: KBC Announcement, 6/4/25)

(continued on page 6)

MEMBER NEWS (continued from page 5)



New York Blood Center Enterprises (NYBCe) recently held a ribbon-cutting ceremony celebrating the opening of its largest donor center. The event included, "leaders from across the region, including Westchester County Executive Ken Jenkins, Westchester County Board of Legislators Chairman Vedat Gashi and Legislator Catherine Parker, Suburban Hospital Alliance of New York State President and CEO Wendy Darwell, and other partners, blood donation advocates, donors, and recipients. According to NYBCe, "[the] state-of-the-art donor center is housed within the 187,000-square-foot master campus — the first single-site home for NYBCe's tri-state operations — bringing together blood collections, life sciences research, processing, and cell therapy manufacturing under one roof. [In addition to the donor center,] the campus includes a comprehensive menu of services and products to support and manage the full spectrum of transfusion medicine, regenerative medicine, and cellular-therapy-related research projects." Andrea Cefarelli, senior vice president at New York Blood Center added in the announcement, "[o]ur stunning Rye donor center is one of the centerpieces of our new campus, one that we hope will become a hub for the Westchester community. This incredible campus allows NYBCe to fulfill our mission of supporting the tri-state area's public health and sharing our life-saving research around the world. We are grateful to the Town of Rye, our local leaders, and everyone who joined us to celebrate this exciting new chapter."

(Source: NYBCe Announcement, 6/19/25)

GLOBAL NEWS

Australian Red Cross Lifeblood (the national blood provider for Australia) announced on June 18th that donor eligibility criteria is being revised for sexually active gay and bisexual men and transgender women who are sexually active with men. Beginning July 14th, "Lifeblood will remove most sexual activity wait times for plasma donations. Under this world-leading 'plasma pathway,' most people, including [sexually active] gay and bisexual men, and anyone who takes pre-exposure prophylaxis (PrEP), will be able to donate plasma without a wait period, providing they meet all other eligibility criteria. Extensive research and mode[l]ing show that there will be no impact to the safety of the plasma supply with this change," according to a statement published by Lifeblood. Additionally, the organization said that it has been, "progressing changes to blood and platele[t] donation eligibility, with the Therapeutic Goods Administration (TGA), Australia's regulatory authority, approving a submission to remove gender-based sexual activity rules. Once implemented, all donors will be asked the same questions about their sexual activity, regardless of their gender or sexuality, and most people in a sexual relationship of six months or more with a single partner will be eligible to donate blood. In addition, most people with new or multiple partners will also be able to donate blood if they have not had anal sex in the last three months. The change will bring an end to men being asked if they've had sex with another man. Unlike other countries with gender-neutral assessments, most people unable to donate blood under the updated gender-neutral rules — including because they are taking PrEP — will still be able to donate plasma in Australia without a wait time."

(Source: Lifeblood Announcement, 6/18/25)

France's national blood provider (EFS) has discovered a new blood type that they are naming "Gwada negative," according to a report from *France 24*. The publication noted that, "[a] French woman from the Caribbean island of Guadeloupe has been identified as the only known carrier of a new

(continued on page 7)

GLOBAL NEWS (continued from page 6)

blood type [and the] announcement was made 15 years after researchers received a blood sample from a patient who was undergoing routine tests ahead of surgery." EFS stated in LinkedIn post last week that, "'[we have] just discovered the 48th blood group system in the world!' This discovery was officially recogni[z]ed in early June in Milan by the International Society of Blood Transfusion (ISBT)." Officials from the EFS further explained to the news outlet that, "a 'very unusual' antibody was first found in the patient in 2011. However, resources at the time did not allow for further research. Scientists were finally able to unravel the mystery in 2019 thanks to 'high-throughput DNA sequencing,' which highlighted a genetic mutation. The patient, who was 54 at the time and lived in Paris, was undergoing routine tests before surgery when the unknown antibody was detected. '[She] is undoubtedly the only known case in the world [and] is the only person in the world who is compatible with herself.' [The patient] inherited the blood type from her father and mother, who each had the mutated gene."

(Source: *France 24*, "The Bright Side: French scientists identify new blood type in Guadeloupe woman,"6/21/25) ♦

COMPANY NEWS

Data published in *The New England Journal of Medicine* demonstrated the safety and efficacy of a gene therapy to treat hemophilia B developed by **CSL Behring**. The paper presented, "data from 10 men with severe hemophilia B treated with a single bolus infusion of scAAV2/8-LP1-hFIXco who were followed for a median of 13 years." The authors explained that, "[b]efore gene therapy, the median annualized bleeding rate was 14.0 episodes (IQR, 12.0 to 21.5) among all 10 participants, including 3 participants who were receiving on-demand treatment. With nearly 13 years of follow-up, the median annualized bleeding rate among all 10 participants was 1.5 episodes (IQR, 0.7 to 2.2), which represented a median rate reduction from the pretreatment period by a factor of 9.7 (IQR, 3.7 to 21.8). [Additionally, the] median annual use of factor IX concentrate before gene therapy was 2613 IU per kilogram (IQR, 1671 to 4513). Over a period of 13 years after the receipt of gene therapy, factor IX concentrate use decreased by a median factor of 12.4 (IQR, 2.21 to 27.1) to 367 IU per kilogram (IQR, 60 to 1597) at 13 years." The authors concluded that, "[i]n this study, 13 years of longitudinal follow-up among men with severe hemophilia B confirmed the long-term safety of AAV gene therapy and durability of factor IX expression, which were accompanied by lasting improvement in hemostasis and a reduction in the use of factor IX prophylaxis."

Citation: Reiss, U.M., Davidoff, A.M., Tuddenham, E., *et al*. "Sustained Clinical Benefit of AAV Gene Therapy in Severe Hemophilia B." *The New England Journal of Medicine*. 2025.

Terumo Blood and Cell Technologies (Terumo BCT) recently announced the publication of a, "new protocol in a paper demonstrating expanded capabilities for its Quantum™ system to unlock rapid CAR-T cell expansion." According to a company news release, "[t]he protocol consolidates the processes of T cell activation, lentiviral vector transduction and expansion of CAR-T cells in a single Quantum system, simplifying procedures that have been highly variable and dependent on a skilled workforce. The protocol demonstrated enhancement in manufacturing efficiency, with a two-fold increase in transduction efficiency over manual culture and the ability to consistently produce over 12 billion CAR-T cells in 7 to 8 days."

(Source: Terumo BCT News Release, 6/18/25)

The U.S. Food and Drug Administration (FDA) has issued a recall for a, "specific lot of the **Fresenius Kabi** Ivenix LVP Blood Products Administration Set. In an agency communication explaining the recall, the FDA noted that reason for the recall was, "[t]he primary and secondary inlet lines were reversed during assembly, which may cause an infusion of unfiltered blood to the patient [and use] of the affected sets may

(continued on page 8)

COMPANY NEWS (continued from page 7)

result in the administration of unfiltered blood or delays in therapy. [Clinical outcomes] can vary from asymptomatic to serious adverse events, especially in vulnerable populations such as neonates, critically ill patients, or those undergoing large-volume transfusions. Short-term and long-term complications will vary depending on the patient population, the underlying condition, health status of the patient, and the treatment regimen. At this time, Fresenius Kabi has not reported any serious injuries or deaths associated with this issue." Questions or requests for additional information about the recall can be directed here."

(Source: FDA Announcement, 6/17/25)

CALENDAR

Note to subscribers: *Submissions for a free listing in this calendar (published weekly) are welcome. Send information to newsletter@americasblood.org. (For a more detailed announcement in the weekly "Meetings" section of the newsletter, please include program information.)*

2025

June 25. **ADRP Webinar: From Partnership to Purpose: Strengthening Hospital Relationships.** Registration is open. More information available here.

Sept. 10-12. **6th European Conference on Donor Health and Management (ECDHM). Wijk aan Zee, the Netherlands.** Registration is open. More information available here.

Sept. 24-25. **2025 ADRP Master Class: "Building Brighter Experiences: Empowering Customers, Engaging Employees (Virtual).** More information is coming soon.

Oct. 12-15. **American Association of Tissue Banks (AATB) Annual Meeting. Atlanta, Ga.** More information is coming soon.

Oct. 14-15. **International Protein Forum. Old Town Alexandria, Va.** Registration opens in July.

Oct. 25-28. **AABB Annual Meeting. San Diego, Calif.** More information is coming soon.

Oct. 26-29. **Blood 2025 and the ISBT 36th Regional Congress. Perth, Australia.** More information available here.

Nov. 12. **2025 ADRP International Showcase.** More information coming soon.

Nov. 13-14. **2025 ABC Women's Executive Leadership Community (WELC) *Rise & Lead Workshop*.** More information available here.

Nov. 17-20. **American Society for Clinical Pathology (ASCP) Annual Meeting. Atlanta, Ga.** Registration is open. More information available here.

2026

Mar. 9-12. **2026 ABC Annual Meeting. Tucson, Ariz.** More information coming soon.

May 12-14. **2026 ADRP Annual Conference. Minneapolis, Minn.** More information coming soon.

CLASSIFIED ADVERTISING

POSITIONS

Reference Laboratory Technologist. Be part of something bigger; change the world with us by joining **ImpactLife's** team. We are seeking a full-time **Medical Laboratory Scientist/Medical Technologist** to join our Blood Banking team. As a Reference Lab Tech with ImpactLife, you will work in our accredited immunohematology reference laboratory, performing specialized testing to serve local hospital clients. For more information including job details, benefits, and compensation click here: Join Us!

Vice President, Blood Services (Eastern and Western Area - Remote). Vitalant is looking for a bold, visionary leader to join our Blood Services Leadership Team as the **Vice President, Eastern Area**. This is a high-impact role, that will focus on deep community and customer engagement, mobile blood drive success, resource management for both mobile and fixed sites, with local facility and fleet oversight. This position works in a highly collaborative manner with leadership throughout the organization to ensure strategic and collection goals are met. **We're Looking for a Proven Senior Leader**

Who Can: Translate enterprise strategy into local execution. Build and lead high-performing teams of senior and mid-level leaders. Cultivate a culture of accountability, learning, and cross-functional partnership. Balance operational excellence with innovation and adaptability. Inspire trust, transparency, and connection across regions and stakeholder groups. **What You Can Expect:** In this high-impact leadership role, you'll receive a **competitive compensation and total rewards package including a robust performance-based bonus plan**—reflecting your years of experience and the vital influence this position has on our mission and long-term success. If you're ready to make a measurable impact on public health through quality leadership, we invite you to join us. Interested applicants can apply at www.vitalant.org/careers.

Medical Laboratory Scientist. LifeSouth Community Blood Centers is looking for experienced Medical Laboratory Scientists, with a passion for making a difference. Current openings are in Gainesville, Florida (Overnight) and Atlanta, Georgia (Multiple shifts available; rotating weekends required). **Legal authorization to work in the United States is required. We do not provide visa sponsorship for this position.** Shift differential applies to eligible evening and overnight hours; **sign-on and relocation bonuses** may also be offered to qualified candidates. Our Medical Laboratory Scientists work in a full-service, accredited immunohematology laboratory following established policies and procedures to resolve complex immunohematology and compatibility problems to provide the safest donor blood for patients in our community. Join us in our mission to make sure blood is available when it's needed most. Visit our careers page to learn more about this position and apply today!

Laboratory Supervisor (Evenings). LifeSouth Community Blood Centers is looking for an experienced **Laboratory Supervisor** with a passion for making a difference to lead our evening shift Immunohematology Reference Laboratory team, in Gainesville, FL. Shift differential applies to eligible evening and overnight hours; **sign-on and relocation bonuses** may also be offered to qualified candidates. **Legal authorization to work in the United States is required. We do not provide visa sponsorship for this position.** In this role, you'll oversee daily operations, ensure adherence to established policies and procedures, and support staff in resolving complex testing and compatibility challenges. You'll play a critical part in identifying and addressing issues that may impact test performance or result reporting, while mentoring and guiding team members to uphold the highest standards of quality and safety. Your leadership will help ensure the delivery of the safest donor blood for patients in our community. We are committed to excellence in customer service and patient care. Join us in our mission to make sure blood is available when it's needed most. Visit our careers page to learn more about this position and apply today!

Quality Assurance Manager. Kentucky Blood Center (KBC) is seeking a Quality Assurance Manager to guide and support organizational adherence to standards issued by regulatory agencies and accrediting organizations. The position is responsible for KBC's compliance with applicable AABB, FDA, CLIA, State, OSHA, EU, and short supply agreement requirements. Reports to the Vice President, Quality and Regulatory Affairs; supervises the QA team. Qualifications include a minimum of a 4-year medical technologist degree (MLS/CLS) with ASCP professional certification and appropriate combination of experience. Must be located in, or willing to relocate to the Lexington, Kentucky area (assistance provided). For more information or to apply, visit https://www.kybloodcenter.org/about-us/careers.

Associate Medical Director/Medical Director. Serve as the physician face of Versiti and Versiti Ohio, translating complex medical issues to educate other physicians, support staff and the public. Opportunities in educational initiatives and clinical/applied research are available within Versiti and with our affiliated health systems. As part of the Versiti physician team you will have the opportunity to participate in clinical research projects with investigators at our world-renowned diagnostic laboratory and blood research institute. Joining our Medical Science Institute transfusion medicine physician team will provide you with a uniquely diverse and collaborative experience. Requirements: MD or DO Degree. Board certified/eligible in Blood Banking/Transfusion Medicine. At least three years of experience in blood center/transfusion medicine practice preferred. Licensed or eligible for an Ohio and Indiana; other state licenses may be required. Driver's License in good standing.

(continued on page 10)

POSITIONS (continued from page 9)

Please click here to read the full job description and apply.

Vice President, Quality and Regulatory Affairs. The Vice President, Quality and Regulatory Affairs leads enterprise-wide quality, compliance, and regulatory initiatives in support of NYBCe's GxP Business Units, including Blood and HCT/P manufacture, analytical laboratories, specialty pharmacy, therapeutics, and medical programs. Reporting to the SVP of Quality and Regulatory Affairs, the VP provides focused oversight of quality systems to ensure compliance with regulatory and corporate requirements. She/he oversees quality-related interactions with clients, including customer audits and the development of quality agreements. The VP establishes a regulatory strategy for product development projects, advises NYBCe leadership on regulatory issues, prepares regulatory submissions, and represents NYBCe to regulatory and accrediting agencies. The VP applies strong leadership skills to motivate, coach, develop, and retain high-performing Quality staff, and fosters a quality-oriented culture throughout the organization. Responsibilities: Lead improvement projects dealing with broad or complex issues, or with strategic impact. Participate in preparation of CMC submissions. **Locations:** Candidates must be able to report into one of the following NYBCe locations: Rye, New York; Kansas City, Missouri; St. Paul, Minnesota; Providence, Rhode Island, and Newark, Delaware. For applicants who will perform this position in New York City or Westchester County, the proposed annual salary is $270,000.00p/yr. to $280,000.00p/yr. Click here to apply.